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ABSTRACT
Objective The incidence of inﬂammatory bowel
disease (IBD) is increasing in Eastern Europe. The
reasons for these changes remain unknown. The aim of
this study was to investigate whether an East–West
gradient in the incidence of IBD in Europe exists.
Design A prospective, uniformly diagnosed, population
based inception cohort of IBD patients in 31 centres
from 14 Western and eight Eastern European countries
covering a total background population of approximately
10.1 million people was created. One-third of the
centres had previous experience with inception cohorts.
Patients were entered into a low cost, web based
epidemiological database, making participation possible
regardless of socioeconomic status and prior experience.
Results 1515 patients aged 15 years or older were
included, of whom 535 (35%) were diagnosed with
Crohn’s disease (CD), 813 (54%) with ulcerative colitis
(UC) and 167 (11%) with IBD unclassiﬁed (IBDU). The
overall incidence rate ratios in all Western European
centres were 1.9 (95% CI 1.5 to 2.4) for CD and 2.1
(95% CI 1.8 to 2.6) for UC compared with Eastern
European centres. The median crude annual incidence
rates per 100 000 in 2010 for CD were 6.5 (range
0–10.7) in Western European centres and 3.1 (range
0.4–11.5) in Eastern European centres, for UC 10.8
(range 2.9–31.5) and 4.1 (range 2.4–10.3), respectively,
and for IBDU 1.9 (range 0–39.4) and 0 (range 0–1.2),
respectively. In Western Europe, 92% of CD, 78% of UC
and 74% of IBDU patients had a colonoscopy performed
as the diagnostic procedure compared with 90%, 100%
and 96%, respectively, in Eastern Europe. 8% of CD
and 1% of UC patients in both regions underwent
surgery within the ﬁrst 3 months of the onset of disease.
7% of CD patients and 3% of UC patients from Western
Europe received biological treatment as rescue therapy.
Of all European CD patients, 20% received only
5-aminosalicylates as induction therapy.
Conclusions An East–West gradient in IBD incidence
exists in Europe. Among this inception cohort—including
indolent and aggressive cases—international guidelines
for diagnosis and initial treatment are not being
followed uniformly by physicians.
Signiﬁcance of this study
What is already known on this subject?
▸ The incidence of inﬂammatory bowel disease
(IBD) is increasing worldwide.
▸ Recent studies from Eastern Europe have
reported sharp increases in incidence in some
centres comparable with Western European
incidence rates, whereas in other Eastern
European centres IBD incidence has not been
investigated. Whether these increases represent
true increases in incidence remains unknown.
▸ Few population based inception cohorts in
adults and paediatric onset IBD exist from
Eastern Europe.
What are the new ﬁndings?
▸ A prospective, population based, web based
inception cohort in 31 European centres
covering a background population of 10.1
million people.
▸ A West–East gradient of 2 in IBD incidence
exists in Europe. The highest incidence in the
world is found on the Faroe Islands.
▸ The patient populations in Eastern and Western
Europe are identical in terms patient
characteristics, disease extent and phenotype,
smoking habits and diagnostic delay.
▸ In this inception cohort, the initial surgery rates
seemed unchanged despite the introduction of
biological therapy in IBD treatment.
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INTRODUCTION
The incidence of inﬂammatory bowel diseases (IBDs), consisting
of Crohn’s disease (CD) and ulcerative colitis (UC), is subject to
considerable variation worldwide. Incidences of UC and CD
vary between 0 and 24.3/100 000 inhabitants and 0 and 20.2/
100 000 inhabitants, respectively,1 with IBD more common in
industrialised countries than in non-industrialised countries.
Until recently, few population based cohort data were available
on the epidemiology of IBD in Eastern Europe. However,
recent studies from Hungary and Croatia have reported sharp
increases in IBD incidence that means they are now comparable
with Western European countries.2 3
The reported increase could be due to methodological bias in
previous studies from Eastern Europe, rising awareness of the
disease, differences in diagnostic practices or they could reﬂect
true changes in IBD incidence.4 To investigate whether there is
an East–West gradient in the incidence of IBD across European
countries, 31 medical centres from Eastern and Western Europe
participated in the European Crohn’s and Colitis Organisation’s
(ECCO) Epidemiological Committee (EpiCom) study; a pro-
spective population based cohort of unselected IBD cases diag-
nosed in 2010 within well described geographical areas was
collated by capturing clinical data throughout a 5 year period
(2010–2015). Epidemiological ﬁndings on incidence, phenotype
and initial treatment are presented here.
METHODS
Study centres
Following an initial meeting in Vienna in 2006 and an
announcement in an ECCO newsletter,5 31 centres from 14
Western and eight Eastern European countries covering a total
background population of approximately 10.1 million people
(6.8 million from Western and 3.3 million from Eastern Europe)
agreed to participate in this study. The classiﬁcation of centres
as being situated in either Western or Eastern European coun-
tries was based on the socioeconomic status of that country
before 1990. A well deﬁned primary catchment area with up to
date population data, including age and gender distribution, was
a prerequisite for participation. Similarly, participation required
an established network of gastroenterologists, colorectal sur-
geons and general practitioners within the uptake area to ensure
complete coverage and inclusion of patients.
A study steering committee has organised twice yearly
EpiCom group meetings since 2006 where participants have
been educated in case ascertainment in order to achieve consist-
ency of methods as well as being trained in how to enter data in
the EpiCom database. Ten centres had previously organised
population based cohorts. Furthermore, participants have been
able to inﬂuence the development and improvement of the web
based database, constructed by HD Support LLC, Denmark.6
The low cost, web based epidemiological concept made partici-
pation possible for every country in Europe, regardless of socio-
economic status and prior experience.
Case deﬁnition
Incident cases diagnosed with IBD between 1 January and 31
December 2010 and living in the predeﬁned catchment areas at
the time of diagnosis were prospectively included. Cases were
required to meet the Copenhagen Diagnostic Criteria for CD7
and UC8 (see web appendix available online only). Cases in
which not of all criteria for either CD or UC were fulﬁlled and
yet in which subsequent relevant IBD treatment was necessary
were classiﬁed as IBD unclassiﬁed (IBDU).7–9 Fulﬁlment of the
aforementioned criteria was ensured by the participating physi-
cians. Diagnostic criteria were locked into the database securing
that the required criteria for CD, UC or IBDU were met.
General practitioners, specialists, other IBD units and patient
self-help groups in the study areas were contacted twice during
the inclusion period to ensure complete prospective recruitment
of patients. Patients younger than 15 years were included as
paediatric patients in the paediatric centres, with the exception
of the centre from the Czech Republic which included patients
younger than 18 years. The age limit of 15 years was the referral
age and was decided on by agreement between all centres.
Disease phenotype classiﬁcation by disease extent for UC, as
well as disease location and behaviour for CD, were deﬁned
according to the Montreal classiﬁcation10 which has previously
been shown to have overall good interobserver agreement.11 12
Induction therapy was deﬁned as any medical or surgical
treatment for IBD initiated within the ﬁrst 3 months after diag-
nosis. Medical treatment was categorised as: 5-aminosalicylates
(5-ASA) (oral and/or topical 5-ASA treatment±topical steroids),
steroids (oral steroids±azathioprine, 6-mercaptopurine, 5-ASA
or topical steroids), immunomodulators (azathioprine,
6-mercaptopurine, ciclosporin±steroids or methotrexate±
steroids) or biological therapy (inﬂiximab or adalimumab in com-
bination with any of the above). Surgical treatment was deﬁned
as any surgery due to IBD within the ﬁrst 3 months after diagno-
sis (regardless of medical treatment prior to surgery).
Data collection and validity
Data regarding demographics, disease course, therapy and blood
samples were collected at diagnosis and every third month
throughout the follow-up period, and data were prospectively
entered by physicians and/or IBD specialist trained nurses into
the EpiCom database,13 a unique, tailor made and secure web
based inception cohort database, facilitating remote data input
from around the world in a cost effective way. Participants were
trained in using the database at the biannual EpiCom meetings
prior to and during the study. Furthermore, participants took
part in the construction and validation process of the database.
Built-in control and validation tests were used to enhance
internal data validity. All data were standardised manually by JB
to further improve data quality, and centres were asked to
correct inconsistent information and to provide any missing
data if necessary.
A running overview bar of the cumulative number of regis-
tered patients and corresponding annual incidence rates for each
centre was implemented at the project website14 to encourage
researchers in entering the data and to meet the deadlines.
Signiﬁcance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ In this European population based cohort, diagnostic
procedures and initial medical treatment were not in
accordance with current guidelines.
▸ Follow-up of the EpiCom cohort will reveal the impact of
treatment choices on disease course.
▸ This web based epidemiological methodology has been
shown to be feasible and affordable regardless of prior
experience and cost constraints, and should be further
developed.
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Audits of case ascertainment and data quality were performed
randomly at 24 of 31 centres, followed by corrections if neces-
sary. The centre from Finland was unable to supply full data on
medical treatment due to local restrictions.
Ethical considerations
The study was approved by the local ethics committees accord-
ing to local regulations.
Statistical methods
Statistical analyses were performed using SAS software V.9.2. Age
and gender standardised annual incidence rates for the adult popu-
lation were obtained using the European Standard population15
with the age groups 0–14, 15–44, 45–64 and 65+years. The pur-
chasing power parity (PPP) version of gross domestic product
(GDP) was obtained for 2011 from the World Bank data service.16
For analysis of a possible GDP effect on IBD incidence, for each
centre the GDP (PPP version) of the corresponding country versus
the centre wise standardised IBD incidence rate (per 100 000
population per year) was depicted. A p value of <0.05 was consid-
ered statistically signiﬁcant. The incidence gradient was analysed
using log linear (multiplicative) Poisson regression.
RESULTS
A total of 1515 patients aged 15 years or older were diagnosed
with IBD in 2010. Of these, 535 (35%) patients were diagnosed
with CD, 813 (54%) with UC and 167 (11%) with IBDU. In
total, 1259 (83%) patients were diagnosed in Western European
and 256 (17%) in Eastern European centres. Paediatric IBD was
diagnosed in 45 patients (see web appendix available online
only). Patient demographics (table 1) were similar in the two geo-
graphic regions, except for educational status. Nearly all cases of
IBDU (96%) were diagnosed in Western European centres.
Disease classiﬁcation (ﬁgures 1, 2) and smoking habits at
Table 1 Demographic characteristics of incident adult and paediatric patients with inflammatory bowel disease
Western European centres Eastern European centres**
Adult patients (≥15 years) CD UC IBDU CD UC IBDU
No of patients (n (%)) 430 (34) 668 (53) 161 (13) 105 (41) 145 (57) 6 (2)
Males (n (%)) 220 (51) 375 (56) 78 (48) 63 (60) 82 (57) 4 (67)
Age (years) (median (range; IQR)) 34 (16–89; 26) 39 (15–89; 27) 38 (16–84; 28) 32 (15–78; 21) 36 (18–81; 26) 30 (20–34; 5)
Time from symptoms to diagnosis (months)
(median (range; IQR))
4.6 (0–31 years;
10 months)
2 (0–21 years;
4.2 months)
2.4 (0–30 years;
5.5 months)
3.4 (0–20 years;
6.5 months)
2.2 (0–5 years;
4.6 months)
2.7 (0–3 years;
8.6 months)
Never smoker (n (%)) 170 (43) 311 (56) 70 (51) 39 (38) 77 (54) 4 (67)
Current smoker (n (%)) 142 (36) 52 (9) 20 (15) 39 (38) 16 (11) 2 (33)
Former smoker (n (%)) 88 (21) 196 (35) 46 (34) 25 (24) 51 (35) 0 (0)
Adult patients (≥15 years) Western European centres Eastern European centres
Educational status (n (%))*
Completed academic education 191 (18) 53 (21)
Completed non-academic education 564 (55) 131 (52)
Currently in education 151 (15) 57 (23)
No education 128 (12) 12 (5)
Employment status (n (%))**
Employed 557 (53) 137 (54)
Self-employed 63 (6) 12 (5)
Unemployed 121 (11) 26 (10)
Student 161 (15) 42 (17)
Retired 157 (15) 36 (14)
Extraintestinal complications at diagnosis (n (%))**
None 1085 (88) 221 (85)
Skin 19 (2) 3 (1)
Eyes 18 (2) 3 (1)
Joints 86 (7) 27 (10)
Primary sclerosing cholangitis 5 (0) 2 (1)
Pancreatitis 3 (0) 2 (1)
Other 13 (1) 3 (1)
Western European centres Eastern European centres**
Paediatric patients CD UC IBDU CD UC IBDU
No of patients (n (%)) 9 (45) 9 (45) 2 (10) 6 (24) 18 (72) 1 (5)
Males (n (%)) 5 (56) 3 (33) 1 (50) 3 (50) 8 (44) 1 (100)
Age (years) (median (range; IQR)) 11 (6–14; 2.1) 12 (1–14; 1.9) 10 (7–14; 3.9) 10 (2–16; 6.2) 4 (1–16; 9.1) 9
Time to diagnosis (months) (median
(range; IQR))
4.1 (0.3–12.4; 2.2) 2.3 (0.6–5.8; 1.9) 1.9 (1.5–2.2; 0.3) 3.6 (2.0–17.0; 2.6) 2.7 (1.2–104.3; 4.3) 3.5
*p<0.01; **NS. p Values are given for comparison between the geographic regions.
CD, Crohn’s disease; IBD, inflammatory bowel disease; IBDU, IBD unclassified; UC, ulcerative colitis.
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diagnosis did not differ. In both Western and Eastern European
centres, more CD patients (36% and 38%) than UC patients (9%
and 11%) were current smokers at the time of diagnosis
(p<0.01) while more UC patients (35% and 35%) than CD
patients (21% and 24%) were former smokers (p<0.01).
Incidence in Europe
The crude as well as age and gender adjusted incidence rates
(per 100 000 per year) for UC, CD and IBDU in the selected
study areas are shown in table 2 and illustrated in ﬁgure 3. The
regional annual incidence rates for IBD combined, and for CD,
UC and IBDU separately, differed signiﬁcantly between Eastern
and Western Europe (p<0.01). The highest incidence of IBD
was found on the Faroe Islands (81.5 per100 000). The overall
annual incidence rates in all Western European centres were
roughly twice as high as rates in all Eastern European centres
for CD (incidence rate ratio (IRR)=1.9, 95% CI 1.5 to 2.4) and
UC (IRR=2.1, 95% CI 1.8 to 2.6). The median crude annual
incidence rate for CD was 6.5 (range 0–10.7) in Western
European centres and 3.1 (range 0.4–11.5) in Eastern European
centres whereas the median annual incidence rates for UC were
10.8 (range 2.9–31.5) and 4.1 (range 2.4–10.3), respectively,
and the median annual rates for IBDU were 1.9 (range 0–39.4)
and 0 (range 0–1.2), respectively.
The observed incidences correlated with the GDP of each
country. The highest incidences were observed in countries
with high GDP—that is, Western European centres (Northern
Europe and the Mediterranean region)—compared with
regions with lower GDP (Eastern European centres) (ﬁgure 4).
Analysing incidence rates depending on age, gender, region
and GDP, the IRR for IBD was 0.4 (95% CI 0.2 to 0.7) when
comparing Eastern with Western European centres for the
same age/gender group and GDP. High concordance prohibited
the separation of the effects of GDP and geographic region in
this analysis. The variation in rates could thus be ascribed to
either factor.
Diagnostic procedures
All UC patients were diagnosed using endoscopy (see web appen-
dix available online only). A full colonoscopy was performed in
524 (78%) UC patients from Western Europe compared with
Figure 2 Disease location and
behaviour at diagnosis for adult
patients with Crohn’s disease (NS).
Figure 1 Extent of disease at diagnosis for adult patients with
ulcerative colitis (UC) (NS).
Burisch J, et al. Gut 2014;63:588–597. doi:10.1136/gutjnl-2013-304636 591
Inﬂammatory bowel disease
 group.bmj.com on August 25, 2014 - Published by gut.bmj.comDownloaded from 
130 (90%) from Eastern European countries (p<0.01) while the
remaining patients had a sigmoidoscopy performed as part of
their diagnostic investigations (proctosigmoiditis patients, where
the investigator reached normal tissue). For CD, 402 (93%)
patients in Western and 101 (96%) in Eastern European countries
had a colonoscopy performed, while 1% in both Western and
Eastern European countries only had a sigmoidoscopy per-
formed during the diagnostic investigation (NS). For patients
with IBDU, 119 (74%) from Western Europe had a colonoscopy
compared with six (100%) from Eastern Europe.
Treatment
The initial treatment in Western and Eastern European centres
during the ﬁrst 3 months of disease is shown in ﬁgure 5. The
observed regional differences for UC and CD patients were signiﬁ-
cant (p<0.01). 5-ASA monotherapy was chosen as the initial treat-
ment for 75 (18%) CD patients in Western Europe and for 33
(31%) in Eastern Europe, with most patients receiving oral 5-ASA
only (66 (92%) and 29 (88%), respectively, NS). Of these patients,
25 (35%) in Western Europe and six (18%) in Eastern Europe had
colonic CD (NS). Of CD patients receiving steroids as the initial
Table 2 Incidence rates per 100 000 for inflammatory bowel disease, Crohn’s disease, ulcerative colitis and inflammatory bowel disease
unclassified in Europe for patients aged 15 years or older in 2010
No of
patients
IBD
crude
IBD adjusted
(SE)
CD
crude
CD adjusted
(SE)
UC
crude
UC adjusted
(SE)
IBDU
crude
IBDU adjusted
(SE)
Western European centres
Cyprus, Nicosia 27 11.2 11.4 (2.2) 6.2 6.3 (1.6) 2.9 3.0 (1.1) 2.1 2.2 (1.0)
Denmark, Aarhus 55 21.2 20.7 (2.8) 8.5 8.2 (1.8) 10.8 10.6 (2.0) 1.9 1.8 (0.8)
Denmark, Amager 23 17.2 16.3 (3.4) 5.2 4.8 (1.8) 7.5 7.4 (2.4) 4.5 4.1 (1.7)
Denmark, Funen 123 30.7 33.4 (3.1) 10.7 11.4 (1.8) 18.7 20.1 (2.4) 1.2 1.4 (0.7)
Denmark, Herlev 48 22.4 24.4 (3.6) 6.5 7.0 (1.9) 7.5 8.3 (2.1) 8.4 9.2 (2.2)
Denmark, Herning 49 21.2 22.5 (3.3) 6.5 7.1 (1.9) 12.6 13.0 (2.5) 2.2 2.3 (1.1)
Denmark, Viborg 37 24.6 26.7 (4.5) 8.6 9.6 (2.7) 14.6 15.7 (3.4) 1.3 1.4 (1.0)
Faroe Islands 31 81.5 83.1 (15.0) 10.5 11.1 (5.6) 31.5 31.8 (9.3) 39.4 40.2 (10.5)
Finland, Pirkanmaa 107 26.2 27.7 (2.7) 4.4 5.0 (1.2) 17.1 18.0 (2.2) 4.7 4.7 (1.1)
Greece, Ioanninia 15 9.2 10.2 (2.6) 3.1 3.5 (1.6) 5.5 6.0 (2.0) 0.6 0.7 (0.7)
Greenland 9 24.0 19.6 (6.6) 0.0 0 (0) 24.0 19.6 (6.6) 0.0 0 (0)
Iceland 72 28.7 28.5 (3.4) 5.6 5.6 (1.5) 17.9 17.8 (2.7) 5.2 5.1 (1.4)
Ireland, Adelaide and
Meath
36 13.2 12.9 (2.2) 4.8 4.3 (1.2) 4.4 4.2 (1.2) 4.0 4.4 (1.4)
Israel, Beer Sheva 51 13.2 13.0 (1.9) 8.6 8.4 (1.5) 4.4 4.4 (1.1) 0.3 0.2 (0.2)
Italy, Northern Italy 182 10.9 11.6 (0.9) 3.9 4.3 (0.5) 6.1 6.4 (0.7) 0.8 0.9 (0.3)
Portugal, Vale de Sousa 31 11.1 10.8 (2.0) 7.2 7.0 (1.6) 3.9 3.8 (1.2) 0.0 0 (0)
Spain, Vigo 102 20.4 21.4 (2.1) 10.2 10.8 (1.5) 9.0 9.4 (1.4) 1.2 1.2 (0.5)
Sweden, Linköping 55 38.3 40.0 (5.4) 9.8 10.1 (2.7) 16.0 16.5 (3.5) 12.5 13.5 (3.2)
Sweden, Örebro 39 26.5 28.3 (4.6) 7.5 8.3 (2.5) 15.6 16.1 (3.4) 3.4 3.9 (1.8)
UK, Brent and Harrow 76 19.9 19.3 (2.2) 2.6 2.4 (0.8) 15.9 15.6 (2.0) 1.3 1.3 (0.6)
UK, Hull and East
Yorkshire
91 18.1 18.6 (2.0) 8.4 8.9 (1.4) 8.2 8.3 (1.3) 1.6 1.4 (0.5)
Eastern European Centres
Croatia, Zagreb 12 6.3 6.6 (1.9) 3.1 3.3 (1.3) 3.1 3.3 (1.4) 0.0 0 (0)
Czech Republic, Prague 22 12.2 12.7 (2.8) 5.5 5.6 (1.8) 5.5 5.8 (1.9) 1.1 1.3 (0.9)
Czech Republic, South
Bohemia
42 7.7 7.9 (1.2) 3.8 3.9 (0.9) 3.8 3.9 (0.9) 0.0 0 (0)
Estonia, Southern
Estonia
30 10.3 11.0 (2.0) 5.2 5.4 (1.4) 5.2 5.7 (1.5) 0.0 0 (0)
Hungary, Veszprem
province
58 23.0 24.0 (3.2) 11.5 12.0 (2.2) 10.3 10.7 (2.1) 1.2 1.3 (0.7)
Lithuania, Kaunas 32 8.5 9.1 (1.6) 2.4 2.6 (0.9) 6.1 6.5 (1.4) 0.0 0 (0)
Moldova, Chisinau 10 4.3 3.9 (1.2) 0.4 0.4 (0.4) 3.9 3.5 (1.2) 0.0 0 (0)
Romania, Timis 24 4.1 4.2 (0.9) 1.7 1.7 (0.5) 2.4 2.5 (0.7) 0.0 0 (0)
Russia, Moscow 26 5.1 5.3 (1.1) 0.8 0.9 (0.5) 4.1 4.2 (0.9) 0.2 0.2 (0.2)
Regional incidence rates
No of
patients IBD (95% CI) CD (95% CI) UC (95% CI) IBDU (95% CI)
All Western European
centres
1259 18.5 (17.5 to 19.5)* 6.3 (5.7 to 6.9)* 9.8 (9.1 to 10.6)* 2.4 (2.0 to 2.8)*
All Eastern European
centres
256 8.1 (7.2 to 9.2) 3.3 (2.7 to 4.0) 4.6 (3.9 to 5.4) 0.2 (0.1 to 0,4)
All centres 1515 15.2 (14.4 to 16.0) 5.4 (4.9 to 5.8) 8.2 (7.6 to 8.7) 1.7 (1.4 to 1.9)
*Difference in incidence between the geographic regions p<0.01.
CD, Crohn’s disease; IBD, inflammatory bowel disease; IBDU, IBD unclassified; UC, ulcerative colitis.
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treatment, 152 (67%) in Western Europe and 53 (93%) in Eastern
Europe received prednisolone while the remaining patients were
treated with budesonide (p<0.01). Of patients receiving budeso-
nide, 44 (58%) in Western Europe and two (50%) in Eastern
Europe had disease located in the terminal ileum (NS). For
patients treated with prednisolone, these numbers were 45% in
Western Europe and 51% in Eastern Europe (NS). Most patients
with UC were treated with 5-ASA monotherapy as the initial treat-
ment. Sixty-nine (44%) patients with left-sided colitis and
19 (23%) with extensive colitis in Western Europe received com-
bination therapy with oral and topical 5-ASA compared with
21 (42%) and six (22%), respectively, in Eastern Europe. Of UC
patients with proctitis, 11 (11%) in Western Europe and ﬁve
(19%) in Eastern Europe received oral 5-ASA only.
Biological therapy
Biological treatment was administered to 29 (7%) CD patients
from Western European centres: 24 (83%) were treated with
inﬂiximab and ﬁve (17%) with adalimumab. Five (17%) patients
were treated ‘top down’, with no medical treatment preceding
biological therapy, while the remaining patients were treated
with combinations of steroids and either azathioprine and/or
5-ASA. An equal proportion of six (21%) patients had strictur-
ing or penetrating disease. In 20 (69%) cases, biological treat-
ment was initiated due to refractoriness to other treatments.
Only two (2%) CD patients from Eastern Europe received
inﬂiximab due to refractoriness to other treatments. Of the 16
(3%) UC patients from Western European centres who received
biological treatment, all received inﬂiximab: three (19%) did
not receive any treatment before starting on biologicals while
the remaining patients were treated with combinations of ster-
oids and either azathioprine and/or 5-ASA or azathioprine
alone. The indication for starting biological treatment was
refractoriness to other treatments in 14 (88%) cases. Most
patients (10 (63%)) had extensive colitis at diagnosis while the
remaining patients had left-sided colitis. Four (3%) patients with
IBDU received inﬂiximab because of refractoriness to other
treatments (two patients), maintenance of remission (one
patient) or steroid dependency (one patient). Three patients
received steroids prior to starting biological treatment while one
patient received 5-ASA monotherapy. No association between
smoking status at diagnosis and biological treatment was
observed in any patient.
Surgery
Resections were performed in 34 (8%) Western European CD
patients (including three hemicolectomies and one total colec-
tomy) compared with eight (8%) Eastern European CD patients
(one hemicolectomy). Stricturing disease occurred in 14 (41%)
Western European patients and penetrating disease in 14 (41%)
compared with two (26%) and ﬁve (63%), respectively, for
Eastern European patients (NS). The majority of patients
(24 (73%) and 7 (88%)) received no medical treatment before
undergoing surgery (NS). Seven (1%) Western European UC
patients (one with left-sided colitis and six with extensive
colitis) underwent a colectomy at diagnosis or during the ﬁrst
3 months of disease compared with one (1%) patient with
Figure 3 Incidence rates (/100 000) of cases aged 15 years or older for inﬂammatory bowel disease (IBD) in selected areas in Europe in 2010.
Figure 4 Inﬂammatory bowel disease (IBD) (Crohn’s disease/
ulcerative colitis/inﬂammatory bowel disease unclassiﬁed) standardised
incidence rates versus 2010/2011 purchasing power parity (PPP) version
of gross domestic product (GDP).
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extensive colitis from Eastern Europe. All UC patients
were treated medically with steroids with or without immuno-
modulators before undergoing surgery. No association between
smoking status at diagnosis and risk of surgery was observed for
either CD or UC patients (NS). Two (1%) patients with IBDU
from Western Europe had a total colectomy at diagnosis or
during the ﬁrst 3 months of disease.
DISCUSSION
We have presented what we believe is the ﬁrst multicentre web
based inception cohort study of the incidence of IBD in Europe.
The overall age and gender adjusted annual incidence rates per
100 000 per year were 5.4 for CD, 8.2 for UC and 1.7 for IBDU.
The combined annual incidence rates for CD and UC in all
Western European centres were twice as high as the rates in all
Eastern European centres. This gradient was smaller than origin-
ally expected compared with the North–South gradient
previously observed17; this might be explained by a bias concern-
ing case ascertainment in previous Eastern European studies.
All 31 participating centres performed a population based
study capturing all incident IBD patients in the catchment area
during 2010. Several measures were used in order to secure the
quality and validity of the incidence rates recorded. Diagnostic
criteria used for case deﬁnition, the time period of inclusion,
the recorded patient data and the method of case ascertainment
were standardised and consistent, and catchment areas were pre-
cisely deﬁned. The uniﬁcation of methods constitutes a major
strength of population based inception cohorts compared with,
for example, Health Administrative Databases, where issues of
data incompleteness compared with clinical records and coding
errors of diagnoses exist.18 19 Furthermore, by contacting all
departments of gastroenterology, practising gastroenterologists
and general practitioners in the uptake areas during the inclu-
sion period, prospective inclusion of all patients in the regions
diagnosed with IBD was ensured. Audit visits and built-in data
Figure 5 Initial treatment during the
ﬁrst 3 months of disease in Eastern
and Western European centres.
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control in the database guaranteed project protocol adherence,
as well as extensive training of participating physicians and
nurses in methodology prior to and during the study period at
the biannual EpiCom group meetings.
The reported IBD incidence rate on the Faroe Islands (81.5
per 100 000 per year) is, to our knowledge, the highest
reported incidence rate to date. Median age at diagnosis and
time to diagnosis did not differ from other Western European
centres (data not shown) and incidence rates for 2011 and 2012
in the Faroe Islands did not differ signiﬁcantly from the inci-
dence rate found in 2010 (K Nielsen, personal communication).
A previous study found a mean incidence rate of 23.9 per
100 000 for 1981–198820 on the Faroe Islands. The present
major increase in incidence could have been caused by environ-
mental factors21 (eg, special dietary habits) in combination with
a genetic burden.22 Another interesting observation was the
Hungarian incidence of IBD (23 per100 000), which was the
highest Eastern European incidence and equalled Western
European incidences. This ﬁnding is in line with previous
reports,2 and as Hungary is one of the wealthier Eastern
European countries in terms of GDP, may be the result of a
more westernised way of life. The analysis suggests that lifestyle
variations, expressed by geographic lifestyle differences com-
bined with PPP, inﬂuence IBD incidence and suggests that the
risk of IBD is linked to the developmental status of the geo-
graphic region/country.
Additionally, previous population based studies have shown
that 5–7% of all cases of IBD occur in children <15 years of
age.23 24 In this inception cohort, however, only 45 (3%) out of
1560 IBD cases were paediatric onset IBD cases. As many centres
participating in the study are low incidence areas, and since the
paediatric incidence rates observed during 2010 do not differ
from previously reported rates from the same countries or
regions,25 26 the observed number of incident paediatric onset
IBD patients is likely to resemble the true number of cases.
The geographic regions of Eastern and Western Europe were
surprisingly similar in terms of sociodemographic characteristics,
time to diagnosis and smoking habits. In accordance with the
available literature, more CD patients were smokers at the time
of diagnosis and more UC patient were former smokers,27 28
and this was the case in both regions. In addition, the anatom-
ical location, disease extent and behaviour at the time of diagno-
sis showed little overall difference. The diagnostic approach for
CD and UC seemed similar in Eastern and Western Europe and
in accordance with the international guidelines for IBD29–34 as
almost 90% of all IBD patients had a full colonoscopy per-
formed as part of the diagnostic workup. However, only 78%
of Western European UC patients and 73% of IBDU patients
had a full colonoscopy performed, compared with 90% and
100% in Eastern Europe.
The IBD patients included in this population based inception
cohort were unselected and represented the broad spectrum of
disease from indolent to severe cases. It is therefore unsurprising
that international guidelines for the diagnosis and treatment of
IBD are not being followed at ‘the clinical frontier’. The obser-
vation that 21% of CD patients were treated with 5-ASA mono-
therapy for induction offers one such example: the efﬁcacy of
5-ASA for inducing remission in CD patients remains uncer-
tain35 and consequently current guidelines do not recommend
5-ASA for CD.34 36 In a Danish cohort of CD patients, a mild
phenotype of patients was recognised as responders to 5-ASA
and were furthermore characterised as dependent on 5-ASA
treatment, thus beneﬁting from monotherapy for a median of
3 years.37 38 Also, budesonide, recommended as the ﬁrst choice
of treatment for ileocaecal CD,36 has recently not shown super-
iority to 5-ASA,38 and 5-ASA is recommended during pregnancy
due to its low toxicity,39 40 which could partly explain the
observed high frequency of 5-ASA as the initial treatment in CD
patients.
With regards to steroid treatment in CD, 33% of Western
European and 7% of Eastern European patients were treated
with budesonide. Yet only 62% and 50%, respectively, had the
disease located in the terminal ileum. Furthermore, although
current guidelines recommend topical therapy with 5-ASA for
active proctitis, and combined therapy with both oral and
topical 5-ASA for mildly to moderately active left-sided and
extensive colitis,41 these were not followed uniformly by partici-
pating physicians. Socioeconomic considerations regarding treat-
ment options inﬂuence the choice of treatment, just as patient
preferences do, and these might be inﬂuenced by psychological
distress, patient beliefs about medication or a discordant
doctor–patient relationship.42 Also, differences in disease man-
agement are strongly linked to extra-medical considerations and
not necessarily linked to the disease itself, while the comparison
might be further complicated by major differences between
health systems across Europe.
Surgery rates for CD have been declining in the past two
decades.43 In a Danish population based cohort, 12% of CD
patients diagnosed between 2003 and 2005 had a resection per-
formed within the ﬁrst year after diagnosis.9 Similarly, in a
population based study from Hungary, CD patients diagnosed
between 2002 and 2006 reported a surgery rate of 9.8% after
1 year.44 The present study found that surgery rates within the
ﬁrst 3 months were already close to what is seen at 1 year of
diagnosis, representing unavoidable surgeries. Biological treat-
ment within the ﬁrst 3 months of disease was administered in
7% of CD and 3% of UC patients from Western Europe. This
rapid escalation of therapy might be the result of the ‘era of
mucosal healing’ as an important treatment goal45 as well as the
use of biological as medical rescue therapy.46 Almost 20% of
both CD and UC patients treated with biologicals were treated
‘top down’ and did not receive any other treatment prior to
biologicals.
In the present study we have shown that it is possible to
perform a large, entirely web based, epidemiological population
based cohort study throughout Europe in 31 centres. The data-
base is inexpensive with low maintenance costs, is easy to use
and facilitates direct remote data input. Most centres had not
performed population based inception cohort studies before but
this innovative methodology enabled participation regardless of
prior experience and cost constraints. The web based epidemio-
logical concept is feasible and the data it generates are valid,
robust and consistent.
The EpiCom study has created this inception cohort, as well
as the related database, as a framework for more epidemio-
logical studies to further analyse the impact of treatment choices
on disease course during follow-up observation in 2010–2015
of the EpiCom cohort, as well as the impact of environmental
factors.
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